title: Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
authors.affiliation: Department of Surgery, College of Pharmacy, University of Tennessee College of Medicine, Memphis, USA.
authors.forename: R R
authors.initials: RR
authors.lastname: Alloway
authors.forename: W C
authors.initials: WC
authors.lastname: Russell
authors.forename: L W
authors.initials: LW
authors.lastname: Gaber
authors.forename: M H
authors.initials: MH
authors.lastname: Amiri
authors.forename: S R
authors.initials: SR
authors.lastname: Vera
authors.forename: A O
authors.initials: AO
authors.lastname: Gaber
mesh_terms: D000293:Adolescent; D000328:Adult; D000681:Amylases / Q000652:urine; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood / Q000652:urine; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000276:immunology*; D012008:Recurrence; D013256:Steroids / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine; D003404:Creatinine; D000681:Amylases; D001379:Azathioprine; D016559:Tacrolimus